 | |
| Clinical data | |
|---|---|
| Trade names | Lacipil, Motens |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~10% |
| Protein binding | >95% |
| Metabolism | Hepatic |
| Onset of action | 30–50 min |
| Eliminationhalf-life | 13–19 hours |
| Excretion | Feces (~70%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.166.373 |
| Chemical and physical data | |
| Formula | C26H33NO6 |
| Molar mass | 455.551 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Lacidipine (tradenamesLacipil orMotens) is acalcium channel blocker. It is available as tablets containing 2 or 4 mg.
It was patented in 1984 and approved for medical use in 1991.[1]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
